7
56 [12] . These above studies showed no consistent findings and few studies were 57 conducted in the Asian population.
58
We aimed to investigate the long-term outcomes of pediatric GD patients who 59 received ATD and identify probable clinical or laboratory factors associated with 60 remission. We documented our 32-year experience in 300 children and adolescents 61 with GD. Patients were classified as remission, relapse, and ongoing ATD groups;
62 clinical and laboratory characteristics were presented and analyzed.
9 80 a starting dose between 2.5 and 30 mg/day, (0.05-0.80 mg/kg/day) depending on the 81 patients' age, body weight, clinical severity, and initial fT4 levels. PTU was only used 82 when the patients could not tolerate the side effect of carbimazole or methimazole.
83 The dose was subsequently titrated and adjusted to maintain euthyroidism. Patients 84 were initially followed at 2-4 weeks interval and then every 3 months after thyroid 85 function test results normalized. ATD was discontinued if euthyroidism was 86 maintained at a low dose (methimazole ≤ 2.5 mg/day) for more than 6-12 months, and 87 the TRAb was near or within the normal range. Remission was defined as the 88 maintenance of euthyroidism ≥ 12 months after ATD was discontinued and no 89 recurrence of thyrotoxicosis was recorded during the follow-up period. Relapse was 90 defined as an elevated fT4, suppressed TSH levels together with restarting ATD use.
91
We obtained informed written consent from the parents or guardians of the 92 children, and the study was approved by Mackay Memorial Hospital institutional 93 review board (18MMHIS156e). In this study, we demonstrated that patients who aged < 5 years, who had no 167 family history of thyroid disease and who had lower TRAb levels were more likely to 168 achieve remission. There were 34% patients who were lost follow-up during the study 169 period. Among patients who continued the ATD treatment, the long-term remission 170 rate in pediatric GD patients was 39.9% after a median of 5.3 years of ATD treatment.
Statistical analysis

171
Our results suggested that GD patients who aged < 5 years had a higher chance 172 to achieve remission and tended to receive ATD for a longer course. as a remission predictor. Because GD is rare in pre-pubertal children, especially in 182 those aged < 5 years, further studies are needed to clarify the relationship between 183 onset age and remission rate.
184
Our study showed that nearly 40% of pediatric GD patients had a family history 185 of thyroid disease, consistent with previous studies in the literature [6, 7, 12, 19]. Our 186 study also revealed that GD patients with a positive family history of thyroid disease 187 were less likely to achieve remission. A similar study performed in 194 adult GD patients also proved that GD patients with a family history of thyroid disorders were 2. 
